Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Krka DDFRA:KN8 -4.47%71 EV-to-EBIT is 13.52 as of Sep. 04, 2026, which is 57% above its 10-year median of 8.63. GuruFocus rates FRA:KN8 with a GF Score™ of 71/100 and a GF Value™ of €209.22 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 682 Drug Manufacturers companies, Krka DD ranks better than 56.3% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Krka DD's Enterprise Value is €7,079 Mil.
Krka DD's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was €524 Mil. Therefore, Krka DD's EV-to-EBIT for today is 13.52.
The historical rank and industry rank for Krka DD's EV-to-EBIT or its related term are showing as below:
FRA:KN8'
s EV-to-EBIT Range Over the Past 10 Years
Min: 5.36 Med: 8.63 Max: 16.84
Current: 13.53
During the past 13 years, the highest EV-to-EBIT of Krka DD was 16.84. The lowest was 5.36. And the median was 8.63.
FRA:KN8's EV-to-EBIT is ranked better than 56.3% of 682
companies
in the Drug Manufacturers industry
Industry Median: 15.985
vs FRA:KN8: 13.53
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Krka DD's Enterprise Value for the quarter that ended in Jun. 2026 was €7,473 Mil.
Krka DD's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €524 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Krka DD EV-to-EBIT Related Terms
Krka DD EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Krka DD's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Krka DD's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Krka DD EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Krka DD's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Krka DD's EV-to-EBIT falls into.
Krka DD's current Enterprise Value is €7,079 Mil.
Krka DD's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €524 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Krka DD (FRA:KN8) has a EV-to-EBIT of 13.52 as of Sep. 04, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Krka DD and its competitors. This is 57% above median its historical median of 8.63. Over the past decade, Krka DD's EV-to-EBIT has ranged from 5.36 to 16.84. According to the industry distribution chart, Krka DD ranks #298 out of 682 companies in the Drug Manufacturers industry, placing it in the top 43.7%.
Is Krka DD's EV-to-EBIT too high?
Krka DD's current EV-to-EBIT of 13.52 is 57% above median its 10-year median of 8.63. Over the past 10 years, this metric has ranged from a low of 5.36 to a high of 16.84. The Drug Manufacturers industry median EV-to-EBIT is 15.99. Krka DD's value of 13.52 is 15.4% below this industry median. Based on the distribution chart, Krka DD ranks #298 out of 682 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Krka DD has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Krka DD's EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Krka DD ranks #298 out of 682 companies for EV-to-EBIT. This puts Krka DD in the upper half of its industry. The industry median EV-to-EBIT is 15.99. Krka DD's value of 13.52 is 15.4% below this benchmark. Historically, Krka DD's own EV-to-EBIT has ranged from 5.36 to 16.84 over the past decade. While the company's 10-year median is 8.63 vs. the industry median of 15.99, Krka DD has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.99, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Krka DD's current EV-to-EBIT of 13.52 is 15.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Krka DD and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Krka DD's current EV-to-EBIT is 13.52, which is 57% above median its own 10-year median of 8.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krka DD stock overvalued right now?
Based on GuruFocus' analysis, Krka DD (FRA:KN8) is currently considered Modestly Overvalued. The stock's GF Value™ is €209.22, compared to a current price of €256.50 — trading 22.6% above its estimated fair value. The current EV-to-EBIT is 13.52, which is 57% above median its 10-year median of 8.63 and 15.4% below the Drug Manufacturers industry median of 15.99. Krka DD's overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Krka DD (FRA:KN8), the current EV-to-EBIT is 13.52 as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Krka DD (FRA:KN8) Overvalued in 2026?
Based on GuruFocus' analysis, Krka DD stock appears to be overvalued.
The current stock price of €256.50 is trading 22.6% above its estimated GF Value™ of €209.22.
GuruFocus considers Krka DD to be Modestly Overvalued.
Key valuation signals for FRA:KN8:
EV-to-EBIT: 13.52 (57% above median its 10-year median of 8.63)
GF Value™: €209.22 vs. price of €256.50 (22.6% above fair value)
Industry Position: 15.4% below the Drug Manufacturers median (#298 of 682)
No single metric tells the full story. See the FRA:KN8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Krka DD engages in the development, production, marketing, and sales of human health products (prescription pharmaceuticals and non-prescription products), animal health products, health resorts, and tourist services. The company's products in Prescription pharmaceuticals include Cardiovascular diseases, Infections, and Oncology; Non-prescription products include Cold and cough products, nasal products, vitamins and minerals, and hair care products; and Animal health products include Antimicrobials and disinfectants, among others. It operates across the European Union, South-East Europe, Eastern Europe region, and Others. The company derives a majority of its revenue from the European Union.
71GF Score
Get the complete analysis for FRA:KN8
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:KN8 has been successfully added to your 
